Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
December 28, 2018
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Feb. 14, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2018 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Feb. 14, 2019. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets medicines, vaccines, and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. ...
December 18, 2018
Zoetis Inc. (NYSE:ZTS) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:00 p.m. EST (9:00 a.m. PST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets medicines, vaccines, and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and ...
December 12, 2018
Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has authorized a $2 billion multi-year share repurchase program as part of its long-term capital allocation plans. The shares are expected to be repurchased over a multi-year period, and the program can be cancelled at any time. The company’s previous $1.5 billion share repurchase program, which was approved in December 2016, is expected to be completed in the first half of next year. The Board of Directors also declared a first quarter 2019 dividend of $0.164 per share, an increase of 30% from the quarterly dividend rate paid in 2018. The dividend is to be paid on Friday, March 1, 2019, to holders of record of the company’s common stock on Friday, January 18, 2019. “As a result of our consistent performance, financial discipline, and the strength of our business model, Zoetis remains well-positioned to generate cash for future growth and value creation opportunities,” said Juan Ramón Alaix, Chief Executive Officer at ...
November 26, 2018
Five-year project prioritized animal pathologies on farms; identified solutions to improve animal health and welfare; and evaluated performance of vaccination and precision farming to predict, detect and prevent diseases PROHEALTH, the largest European Commission-funded livestock agriculture research project, culminated today having identified the most common and costly health threats and potential solutions to sustainable livestock production. The project focused on disease threats associated with the intensity of production in swine herds and poultry flocks and recommended innovative prediction, prevention and detection solutions to improve animal health and increase productivity, while limiting environmental impact and preserving profitability for livestock farmers. The PROHEALTH consortium involved more than 100 scientists and 22 partners from academia, industry and private enterprise, with Zoetis as the sole animal health company partner. The collaboration focused on connecting ...
November 1, 2018
Reports Revenue of $1.5 Billion, Growing 10%, and Net Income of $347 Million, or $0.71 per Diluted Share, Growing 16%, on a Reported Basis for Third Quarter 2018 Reports Adjusted Net Income of $403 Million, or Adjusted Diluted EPS of $0.83, for Third Quarter 2018 Delivers 12% Operational Growth in Revenue and 32% Operational Growth in Adjusted Net Income for Third Quarter 2018 Updates Full Year 2018 Revenue Guidance to $5.750 - $5.800 Billion and Diluted EPS of $2.81 - $2.90 on a Reported Basis, or $3.08 - $3.13 on an Adjusted Basis Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2018 and updated its guidance for full year 2018. The company reported revenue of $1.5 billion for the third quarter of 2018, an increase of 10% compared with the third quarter of 2017. Net income for the third quarter of 2018 was $347 million, or $0.71 per diluted share, an increase of 16% on a reported basis. Adjusted net income 1 for the third quarter of 2018 was $403 ...
October 26, 2018
Zoetis Inc. (NYSE:ZTS) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, Nov. 13, 2018, in Scottsdale, Ariz. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:35 am ET (8:35 am MT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock ...
October 10, 2018
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a fourth quarter 2018 dividend payable to holders of the company’s common stock of $0.126 per share. The dividend is to be paid on Monday, Dec. 3, 2018, to holders of record on Tuesday, Nov. 20, 2018. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press release ...
September 28, 2018
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 1, 2018. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2018 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Nov. 1, 2018. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves ...
September 25, 2018
Zoetis recognized by Working Mother Magazine for its career advancement opportunities, female representation, work-life programs, and health and wellness benefits Roni Thebo named Zoetis’ 2018 Working Mother of the Year Zoetis Inc . (NYSE:ZTS) today announced that it has been named one of Working Mother Magazine’s "100 Best Companies for Working Mothers" for the fifth consecutive year. The publication selects the top 100 companies in the U.S. that lead in areas of female representation and advancement, benefits, parental leave, childcare and flexible work arrangements. “We are excited to once again be among Working Mother Magazine’s top companies,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications at Zoetis. “We strive to create an atmosphere where colleagues can give their best every day. We are honored to be recognized for our leadership in establishing policies, programs and a corporate culture that helps colleagues build rewarding ...
September 24, 2018
Zoetis Inc. (NYSE:ZTS) will participate in the 2018 Cantor Global Healthcare Conference on Monday, Oct. 1, 2018, in New York, N.Y. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Genetics and Aquatic Health, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of ...
September 14, 2018
First monoclonal antibody (mAb) licensed for the treatment of allergic and atopic dermatitis in dogs Zoetis today announced that the U.S. Department of Agriculture (USDA) has granted an expanded indication for Cytopoint ® , a novel monoclonal antibody (mAb) therapy for the treatment of allergic dermatitis in dogs. Cytopoint is the first mAb therapy licensed to treat allergic as well as atopic dermatitis, an indication for which it was fully licensed by the USDA in 2016. Administered every four to eight weeks, one injection of Cytopoint works by targeting and neutralizing interleukin-31 (IL-31), a key protein involved in triggering itch in dogs, offering both convenience and sustained efficacy. “This approval gives veterinarians much needed flexibility for personalized treatment of allergic and atopic dermatitis in dogs with two therapeutic approaches – the injectable Cytopoint and the oral tablet Apoquel,” said Thomas P. Lewis II, DVM, DACVD, Dermatology for Animals in Gilbert, ...
August 22, 2018
An important strategic partnership to improve fish health in Vietnam PHARMAQ, a business of the leading global animal health company Zoetis, today announced a long-term strategic partnership agreement with Vinh Hoan, the world’s leading producer and exporter of pangasius with headquarters in Vietnam. The agreement was signed during the VIETFISH Exhibition in Ho Chi Minh City by Mrs. Truong Thi Le Khanh, Chairwoman of Vinh Hoan, and Mr. Morten Nordstad, President of PHARMAQ The ceremony was attended by Mr. Vũ Văn Tám, Deputy Minister of the Ministry of Agriculture and Rural Development in Vietnam.’ The collaboration involves large scale vaccination of pangasius with ALPHA JECT Panga 2, a PHARMAQ vaccine which protects against disease caused by the bacteria Edwardsiella Ictaluri and Aeromonas Hydrophila. PHARMAQ will also provide Vinh Hoan with fish health services, diagnostic testing, and the introduction of new technologies and R&D activities. “PHARMAQ has been present in Vietnam for ...
August 13, 2018
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.5 billion of senior notes, consisting of $300 million aggregate principal amount of floating rate senior notes due 2021, $300 million aggregate principal amount of 3.250% senior notes due 2021, $500 million aggregate principal amount of 3.900% senior notes due 2028 and $400 million aggregate principal amount of 4.450% senior notes due 2048, in an underwritten public offering. Zoetis intends to use the net proceeds to repay $500 million drawn under the 364-day revolving credit facility entered into on July 27, 2018, repay $500 million issued under its commercial paper program, and for general corporate purposes. The offering is expected to close on August 20, 2018, subject to customary closing conditions. Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and MUFG Securities Americas Inc. are acting as joint book-running managers of the ...
August 2, 2018
Reports Revenue of $1.4 Billion, Growing 12%, and Net Income of $384 Million, or $0.79 per Diluted Share, Growing 55% and 58%, respectively, on a Reported Basis for Second Quarter 2018 Reports Adjusted Net Income of $375 Million, or Adjusted Diluted EPS of $0.77, for Second Quarter 2018 Delivers 9% Operational Growth in Revenue and 37% Operational Growth in Adjusted Net Income for Second Quarter 2018 Updates Full Year 2018 Revenue Guidance to $5.700 - $5.800 Billion and Diluted EPS of $2.72 - $2.89 on a Reported Basis, or $3.00 - $3.10 on an Adjusted Basis Zoetis Inc . (NYSE:ZTS) today reported its financial results for the second quarter of 2018 and updated its guidance for full year 2018. The company reported revenue of $1.4 billion for the second quarter of 2018, an increase of 12% compared with the second quarter of 2017. Net income for the second quarter of 2018 was $384 million, or $0.79 per diluted share, an increase of 55% and 58%, respectively, on a reported basis. Adjusted ...
July 31, 2018
Announcement follows Abaxis shareholder approval of the transaction Enhances Zoetis’ presence in veterinary diagnostics, a category of the animal health industry with approximately 10% compound annual growth over the last three years 1 Purchase price of US $83 per share in cash, or approximately $2.0 billion in aggregate Zoetis Inc. (NYSE: ZTS) today announced the completion of the acquisition of Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate. The acquisition, which was first announced on May 16 , follows the satisfaction of all conditions to the closing, including the receipt of the approval of the acquisition by Abaxis shareholders at a shareholder meeting earlier today. It enhances Zoetis’ presence in veterinary diagnostics, a category of the animal health industry with approximately 10% compound annual growth over the last three ...
July 6, 2018
Zoetis Inc. (NYSE:ZTS) and Abaxis, Inc. (NASDAQ:ABAX) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Zoetis’ previously-announced acquisition of Abaxis for US $83.00 per share in cash, or approximately $2.0 billion in aggregate. The expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transaction. The transaction is subject to other customary closing conditions, including the approval of Abaxis shareholders. Abaxis shareholders will vote on the transaction at a special meeting of shareholders currently scheduled to be held on July 31, 2018. Zoetis expects to complete the acquisition shortly after the Abaxis special meeting if all of the conditions to closing are then satisfied, and it intends to fund the purchase through a combination of existing cash and new debt. About Zoetis Zoetis is the leading ...
June 29, 2018
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 2, 2018. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2018 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Aug. 2, 2018. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves ...
June 6, 2018
Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 5:10 p.m. ET (4:10 p.m. CT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise ...
June 6, 2018
Collaboration will also generate preclinical data to inform Regeneron’s development of human medicines Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Zoetis Inc. (NYSE:ZTS) today announced a five-year collaboration to research the use of Regeneron’s monoclonal antibody therapeutics in animals and discover new veterinary treatments. Under the terms of the agreement, Regeneron has granted Zoetis a license for its VelocImmune ® antibody technology, which Zoetis will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals. In particular, Zoetis is exploring treatments for animals with allergic and immune-related conditions, pain, inflammatory disease and cancer. VelocImmune is Regeneron’s proprietary technology in which the immune system of mice is genetically humanized, enabling the creation of fully-human and optimized antibody drug candidates. Regeneron will receive a license fee, approval and sales milestone payments and royalties ...
May 22, 2018
Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2018 Dental & Veterinary Conference on Wednesday, May 30, 2018, in New York, N.Y. Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, will represent the company and respond to questions from analysts. She is scheduled to present at 11:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis ...
May 16, 2018
Purchase price of US $83 per share in cash, or approximately $2.0 billion in aggregate Enhances Zoetis’ presence in veterinary diagnostics, a category of the animal health industry with approximately 10% compound annual growth over the last three years 1 Brings to Zoetis a proven line of diagnostic instruments and consumables, providing a new platform for growth that Zoetis can accelerate with sales of its products in more than 100 countries Further enables Zoetis to support veterinarians with comprehensive solutions to predict, prevent, detect and treat diseases in animals Affirms strategy to deploy capital in complementary, high-growth segments of animal health industry Zoetis Inc . (NYSE:ZTS) and Abaxis, Inc. (NASDAQ:ABAX) today announced a definitive merger agreement pursuant to which Zoetis will acquire Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 ...
May 15, 2018
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a third quarter 2018 dividend payable to holders of the company’s common stock of $0.126 per share. The dividend is to be paid on Tuesday, Sept. 4, 2018, to holders of record on Friday, July 20, 2018. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press release ...
May 15, 2018
Speaking to shareholders at the Zoetis Inc . (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief Executive Officer Juan Ramón Alaix discussed the company’s strong performance over the past five years and strategies for continued growth as the leader in the global animal health industry. “In 2017, we delivered our fifth consecutive year of operational revenue growth and increased profitability based on deep relationships with customers, innovative research and development, and high-quality manufacturing and supply,” said Alaix. “As we look to the future, we are energized by the growth opportunities in animal health that will keep us on the path of continued industry leadership, and we remain firmly committed to delivering on the long-term value proposition that has generated returns for our investors.” Zoetis Chairman Michael McCallister presided over the business portion of the meeting and shareholder voting. Preliminary results of shareholder voting from the meeting are as ...
May 2, 2018
Reports Revenue of $1.4 Billion, Growing 11%, and Net Income of $352 Million, or $0.72 per Diluted Share, Growing 48% and 50%, respectively, on a Reported Basis for First Quarter 2018 Reports Adjusted Net Income of $365 Million, or Adjusted Diluted EPS of $0.75, for First Quarter 2018 Delivers 7% Operational Growth in Revenue and 34% Operational Growth in Adjusted Net Income for First Quarter 2018 Reaffirms Full Year 2018 Revenue Guidance of $5.675 - $5.800 Billion and Diluted EPS of $2.77 - $2.93 on a Reported Basis, or $2.96 - $3.10 on an Adjusted Basis Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2018 and reaffirmed its guidance for full year 2018. The company reported revenue of $1.4 billion for the first quarter of 2018, an increase of 11% compared with the first quarter of 2017. Net income for the first quarter of 2018 was $352 million, or $0.72 per diluted share, an increase of 48% and 50%, respectively, on a reported basis. This increase ...
May 1, 2018
Zoetis Inc. (NYSE: ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers by Forbes Magazine for the third year in a row. “We are honored to once again be named one of America’s Best Employers by Forbes Magazine,” said Roxanne Lagano, Executive Vice President and Chief Human Resources Officer. “At Zoetis, we know our people drive our success. Our colleagues are proud of our company culture and the meaningful role we play in caring for animals. When it comes to our culture, our Core Beliefs are the foundation of our success. They have helped us create an award-winning workplace and become a leading partner of choice in animal health.” Forbes determined its America’s Best Employers list based on an independent survey among a sample of 30,000 American employees working for companies with at least 1,000 people in their U.S. operations. The willingness to recommend one's own employer was used as the most important factor in ...
April 26, 2018
Company begins construction of state-of-the-art vaccine manufacturing and research and development facilities in Suzhou to support growth Operations to focus on development and manufacturing of vaccines for pigs, cattle and fish and companion animals tailored to the animal health needs of China Zoetis Inc . (NYSE: ZTS) today celebrated the start of construction on a combined global manufacturing and supply and research and development center in Suzhou, China, with a traditional groundbreaking ceremony. The new facility will focus on development and production of quality vaccines for swine, cattle, fish and companion animals that help protect against the strains of diseases prevalent in China. Zoetis also marked the opening of an interim research and development facility nearby in Suzhou where the company’s PHARMAQ business will begin to develop vaccines for the farmed fish industry in China; the first such R&D center established by a multinational company to concentrate on aquaculture ...
April 23, 2018
Marks accomplishments in first year of the African Livestock Productivity and Health Advancement (A.L.P.H.A) Initiative Zoetis today reported on progress during the first year of its African Livestock Productivity and Health Advancement initiative (A.L.P.H.A.) to establish sustainable veterinary diagnostic networks and animal health infrastructure in Uganda, Nigeria, and Ethiopia. The initiative, funded by a $14.4 million grant from the Bill & Melinda Gates Foundation, aims ultimately to improve livestock health and positively impact farmers’ livelihoods in sub-Saharan Africa. In year one of this three-year initiative, Zoetis established the main hubs and basic infrastructure required. This included hiring a team to address regulatory and technical issues; increasing the reliable supply of quality veterinary medicines, diagnostics and services; engaging with local farmers and veterinarians to ensure sustainable solutions; developing veterinary laboratory networks and conducting ...
March 29, 2018
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Wednesday, May 2, 2018. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2018 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on May 2, 2018. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves ...
February 21, 2018
Zoetis Inc. (NYSE:ZTS) will participate in the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018, in Boston, Mass. Clint Lewis, Executive Vice President and President, International Operations, will represent the company and respond to questions from analysts. He is scheduled to present at 8:40 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, ...
February 15, 2018
For Fourth Quarter 2017, Zoetis Reports Revenue of $1.5 Billion, and Net Income of $81 Million, or $0.16 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $341 Million, or Adjusted Diluted EPS of $0.69, for Fourth Quarter 2017 Delivers 13% Operational Growth in Revenue and 37% Operational Growth in Adjusted Net Income for Fourth Quarter 2017 For Full Year 2017, Zoetis Reports Revenue of $5.3 Billion and Net Income of $864 Million, or $1.75 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $1.185 Billion, or Adjusted Diluted EPS of $2.40, for Full Year 2017 Delivers 8% Operational Growth in Revenue and 21% Operational Growth in Adjusted Net Income for Full Year 2017 Company Records One-Time Provisional Net Tax Charge of $212 Million Related to Recently Enacted Tax Legislation in the U.S. Provides Full Year 2018 Revenue Guidance of $5.675 - $5.800 Billion, with Diluted EPS of $2.77 - $2.93 on a Reported Basis, or $2.96 - $3.10 on an Adjusted Basis ...
February 13, 2018
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a second quarter 2018 dividend payable to holders of the company’s common stock of $0.126 per share. The dividend is to be paid on Friday, June 1, 2018, to holders of record on Friday, April 20, 2018. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press release ...
February 12, 2018
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Animal Health Summit on Monday, Feb. 26, 2018, in New York, NY. Glenn David, Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 9:35 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for ...
February 1, 2018
Recognizes USDA and Zoetis’ accomplishments to help America’s farmers produce safe, abundant food from healthy animals Highlights State of Michigan initiatives to create a positive business climate for companies to locate, expand and create new jobs in the state Highlights innovation that helps veterinarians and farmers better predict, prevent, detect and treat disease in animals Zoetis Inc . (NYSE:ZTS), the leading global animal health company, today celebrated its fifth anniversary since becoming a public company by hosting U.S. Secretary of Agriculture Sonny Perdue and Governor Rick Snyder of Michigan for a special town hall meeting at the company’s global research and development headquarters in Kalamazoo, Mich. Zoetis Chief Executive Officer Juan Ramón Alaix; Dr. Catherine Knupp, Executive Vice President and President, Research and Development; and Kristin Peck, Executive Vice President and President, U.S. Operations, led the event, which was attended by more than 500 colleagues. ...